In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other firms that kicked off the trading week stronger. The stock market began ...

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 94.9% in the afternoon session after the company announced that its Phase 3 trial (ROSELLA) met its goal of improving ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little ...

It comes despite overwhelming opposition to the proposal which was one of three options which has been considered for the future Henry Cort Community College as well as meet the needs of the ...

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of ...

In this article, we are going to take a look at where Corcept Therapeutics Incorporated (NASDAQ:CORT) stands against other Guru stocks to invest in. Wall Street seems to be breathing a little easier ...

Controversial plans to relocate The Henry Cort school in Fareham to a new site in North Whiteley have been given the final go-ahead despite continuing opposition from the local community.

Councillors have agreed to relocate a school despite fierce opposition. Henry Cort school in Fareham will now move to a location in North Whiteley from September 2027. The decision was made by ...

Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its Phase 3 ROSELLA trial, which assessed the efficacy ...

Shares of Corcept Therapeutics Incorporated CORT were up a staggering 109.1% on March 31 after the company announced data from the phase III ROSELLA study, which evaluated its pipeline candidate ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) just the other day announced that it had achieved the primary endpoint of its pivotal phase 3 ROSELLA study. This late-stage study tested the ...

or the purchase of call options or similar derivatives in CORT over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other ...